Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-n9wrp Total loading time: 0 Render date: 2024-07-19T10:28:32.961Z Has data issue: false hasContentIssue false

6 - Therapeutic decision making in BMT/SCT for chronic lymphatic leukemia

Published online by Cambridge University Press:  05 August 2013

By
Nebu V. Koshy ,
Reinhold Munker ,
Hillard M. Lazarus  and
Kerry Atkinson
Edited by
Reinhold Munker ,
Gerhard C. Hildebrandt ,
Hillard M. Lazarus  and
Kerry Atkinson
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Gerhard C. Hildebrandt
Affiliation:
University of Utah
Hillard M. Lazarus
Affiliation:
Ireland Cancer Center, Case Western Reserve University Hospital, Cleveland
Kerry Atkinson
Affiliation:
University of Queensland
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
The BMT Data Book
Including Cellular Therapy
 , pp. 67 - 76
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Binet, JL, Auquier, A, Dighiero, G, et al. 1981. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48: 198–206.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
Binet, JL, Caligaris-Cappio, F, Catovsky, D, et al. 2006. Perspective on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107: 859–861.CrossRefGoogle Scholar
Brown, JR, Stevenson, K, Kim, HT, et al. 2008. Comparative outcome of myeloablative and reduced intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia. Blood 112: 972.Google Scholar
Brown, JR. 2011. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011: 110–118.Google ScholarPubMed
Calin, GA, Pekarsky, Y, & Croce, CM. 2007. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20: 425–437.CrossRefGoogle ScholarPubMed
Döhner, H, Stilgenbauer, S, Benner, A, et al. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910–1918.CrossRefGoogle ScholarPubMed
Dreger, P, Corradini, P, Kimby, E, et al. 2007. Indications for stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21: 12–17.CrossRefGoogle ScholarPubMed
Dreger, P, Dohner, H, Ritgen, M, et al. 2010. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116: 2438–2447.CrossRefGoogle Scholar
Gladstone, DE & Fuchs, E. 2012. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Oncol 24: 176–181.CrossRefGoogle ScholarPubMed
Gribben, JG, Zahrieh, D, Stephans, K, et al. 2005. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 106: 4389–4396.CrossRefGoogle ScholarPubMed
Hallek, M, Fischer, K, Fingerle-Rowson, G, et al. 2010. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomized, open-label, phase 3 trial. Lancet 376: 1164–1174.CrossRefGoogle ScholarPubMed
Jantunen, E, Itälä, M, Siitonen, T, et al. 2006. Autologous stem cell transplantation in patients with chronic lymphocytic leukaemia: the Finnish experience. Bone Marrow Transplant 37: 1093–1098.CrossRefGoogle ScholarPubMed
Keating, MJ, Flinn, I, & Jain, V. 2002. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine. Blood 99: 3554–3561.CrossRefGoogle ScholarPubMed
Khouri, IF, Bassett, R, Pondexter, N, et al. 2011. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer 117: 4679–4688.CrossRefGoogle Scholar
Michallet, M, Archimbaud, E, Bandini, G, et al. 1996. HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Intern Med 124: 311–315.CrossRefGoogle ScholarPubMed
Rai, KR & Han, T. 1990. Prognostic factors and clinical staging in chronic lymphocytic leukemia. Hematol Oncol Clin North Am 4: 447–451.CrossRefGoogle ScholarPubMed
Rai, KR, Sawitsky, A, Cronkite, EP, et al. 1975. Clinical staging of chronic lymphocytic leukemia. Blood 46: 219–234.Google ScholarPubMed
Sorror, ML, Maris, MB, Sandmaier, BM, et al. 2005. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 23: 3819–3829.CrossRefGoogle ScholarPubMed
Sorror, ML, Storer, B, Sandmaier, BM, et al. 2010. Impacts of cytogenetic abnormalities and prior alemtuzumab on outcomes of patients (pts) with high-risk chronic lymphocytic leukemia (CLL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). Blood 116: 2364.Google Scholar
Wright, SJ, Robertson, LE, O’Brien, S, et al. 1994. The role of fludarabine in haematological malignancies. Blood Rev 8: 125–134.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×